Fangqin Xue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fangqin Xue has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
Chao Xu
Department of Gastrointestinal Surgery and Department of Radiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou 350001, China
11 shared publications- Yao Lin
Affiliated People’s Hospital, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Fujian-Hong Kong-Macau-Taiwan Collaborative Laboratory for the Inheritance and Innovation of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, The Academy of Rehabilitation Industry, Fujian University of Traditional Chinese Medicine, China
9 shared publications - Qingshui Wang
Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China
7 shared publications Xiangyu Wang
Department of Gastrointestinal Surgery Shengli Clinical Medical Fujian Provincial Hospital College of Fujian Medical University Fuzhou University Affiliated Provincial Hospital 350001 Fuzhou China
5 shared publications- Xiaolong Liu
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, P. R. China
4 shared publications - Guohua Yang
Department of Oncology Surgery, Fujian Provincial Hospital, Fuzhou 350001, China
3 shared publications
Latest Publications
- Open Access
- 25 July 2026
- Published by Elsevier in Phytomedicine
- Vol. 160, 158634
Licochalcone C suppresses gastric cancer progression and enhances 5-FU chemosensitivity by targeting RAC3-mediated PI3K-AKT-mTOR signaling
- 25 July 2026
- Published by Elsevier in Phytomedicine
- Vol. 160, 158634
Open AccessLicochalcone C suppresses gastric cancer progression and enhances 5-FU chemosensitivity by targeting RAC3-mediated PI3K-AKT-mTOR signaling
- Open Access
- 19 June 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Serum FAP⁺ exosome-based flow cytometric detection: potential utility in early diagnosis, disease progression assessment, and surgical response monitoring of lung adenocarcinoma
Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality, and currently available serum biomarkers have limited sensitivity and specificity for early diagnosis. We investigated whether serum fibroblast activation protein-positive (FAP⁺) exosomes could serve as a minimally invasive biomarker for LUAD. We examined FAP expression and exosomal localization in cancer-associated fibroblasts (CAFs), evaluated a magnetic bead-based strategy for enriching FAP⁺ exosomes, and established a latex bead-based flow cytometric assay using biotinylated anti-FAP antibody and streptavidin-PE detection. The assay was then evaluated in healthy donors (HD), patients with benign lung lesions (LBL), and patients with LUAD, and its diagnostic performance was compared with conventional serum biomarkers, including CEA, NSE, and CYFRA21-1. Exosomes released by CAFs showed elevated FAP expression, and FAP was associated with the exosomal marker CD9, supporting a possible CD9-associated exosomal sorting mechanism. In the clinical cohort, serum FAP⁺ exosome levels were significantly higher in LUAD than in HD and LBL, and increased with disease stage. In early-stage LUAD, serum FAP⁺ exosomes showed favorable diagnostic performance, with an AUC of 0.932, 88.4% sensitivity, and 87.6% specificity. Compared with conventional serum biomarkers, including CEA, NSE, and CYFRA21-1, serum FAP⁺ exosomes showed superior diagnostic performance in this cohort, while combined biomarker models provided only modest incremental improvement over FAP⁺ exosomes alone. Serum FAP⁺ exosome levels also decreased significantly after surgery, suggesting that this marker may reflect early postoperative changes. This study provides evidence that FAP is enriched in exosomes released by CAFs and may be incorporated into exosomes through a CD9-associated mechanism. We further established a serum FAP⁺ exosome-based flow cytometric assay that may serve as a promising minimally invasive strategy for LUAD diagnosis, disease progression assessment, and early postoperative monitoring.
- 19 June 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessSerum FAP⁺ exosome-based flow cytometric detection: potential utility in early diagnosis, disease progression assessment, and surgical response monitoring of lung adenocarcinoma
Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality, and currently available serum biomarkers have limited sensitivity and specificity for early diagnosis. We investigated whether serum fibroblast activation protein-positive (FAP⁺) exosomes could serve as a minimally invasive biomarker for LUAD. We examined FAP expression and exosomal localization in cancer-associated fibroblasts (CAFs), evaluated a magnetic bead-based strategy for enriching FAP⁺ exosomes, and established a latex bead-based flow cytometric assay using biotinylated anti-FAP antibody and streptavidin-PE detection. The assay was then evaluated in healthy donors (HD), patients with benign lung lesions (LBL), and patients with LUAD, and its diagnostic performance was compared with conventional serum biomarkers, including CEA, NSE, and CYFRA21-1. Exosomes released by CAFs showed elevated FAP expression, and FAP was associated with the exosomal marker CD9, supporting a possible CD9-associated exosomal sorting mechanism. In the clinical cohort, serum FAP⁺ exosome levels were significantly higher in LUAD than in HD and LBL, and increased with disease stage. In early-stage LUAD, serum FAP⁺ exosomes showed favorable diagnostic performance, with an AUC of 0.932, 88.4% sensitivity, and 87.6% specificity. Compared with conventional serum biomarkers, including CEA, NSE, and CYFRA21-1, serum FAP⁺ exosomes showed superior diagnostic performance in this cohort, while combined biomarker models provided only modest incremental improvement over FAP⁺ exosomes alone. Serum FAP⁺ exosome levels also decreased significantly after surgery, suggesting that this marker may reflect early postoperative changes. This study provides evidence that FAP is enriched in exosomes released by CAFs and may be incorporated into exosomes through a CD9-associated mechanism. We further established a serum FAP⁺ exosome-based flow cytometric assay that may serve as a promising minimally invasive strategy for LUAD diagnosis, disease progression assessment, and early postoperative monitoring.
- 15 April 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 216, 379-388
Stimuli-responsive copper–iodide nanoparticles for low-dose X-ray-induced photodynamic therapy and enhanced cuproptosis
- 15 April 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 216, 379-388
Stimuli-responsive copper–iodide nanoparticles for low-dose X-ray-induced photodynamic therapy and enhanced cuproptosis
- 17 November 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (47) , 64309-64321
Selenium-Enriched Cerium Oxidative Nanoplatform for Colorectal Tumor Surgery with the Guidance of NIR II Fluorescent Bioimaging and Tumor-Microenvironment Triggered Synergistic Therapy
Colorectal cancer (CRC) is the second most fatal and the third most common malignancy globally, posing a substantial challenge in malignant tumor therapy. To solve this issue, we introduce a novel Ce-Se oxide nanovesicle that incorporates indocyanine green (ICG) (Ce-Se&I). Upon surface modification with RGD (Ce-Se&IR), this advanced nanoplatform exhibits precise tumor targeting and is able to activate to produce potent reactive oxygen species (ROS) under tumor microenvironments with acidic and high-H2O2 conditions. Enhanced in vivo fluorescent bioimaging, with higher tumor-to-background ratios, allows for the accurate delineation of tumor boundaries from healthy tissue. Guided by second-near-infrared region (NIR II, 1000-1700 nm) luminescence imaging, tumors are entirely removed, resulting in minimal in situ tumor recurrence or multiorgan metastasis within 30 days postsurgery. Furthermore, with 808 nm laser illumination, the nanoplatform demonstrates a satisfactory photothermal conversion ability, which induces localized tumor thermal and further enhances ROS generation through the synergistic action of bimetallic ions, facilitating CRC cell destruction. These findings highlight the promising potential of Ce-Se oxide nanocomposites with tumor-microenvironment stimuli as a fluorescence bioimaging contrast agent and oxidative therapy nanoagent for cancer eradication, particularly under laser activation.
- 17 November 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (47) , 64309-64321
Selenium-Enriched Cerium Oxidative Nanoplatform for Colorectal Tumor Surgery with the Guidance of NIR II Fluorescent Bioimaging and Tumor-Microenvironment Triggered Synergistic Therapy
Colorectal cancer (CRC) is the second most fatal and the third most common malignancy globally, posing a substantial challenge in malignant tumor therapy. To solve this issue, we introduce a novel Ce-Se oxide nanovesicle that incorporates indocyanine green (ICG) (Ce-Se&I). Upon surface modification with RGD (Ce-Se&IR), this advanced nanoplatform exhibits precise tumor targeting and is able to activate to produce potent reactive oxygen species (ROS) under tumor microenvironments with acidic and high-H2O2 conditions. Enhanced in vivo fluorescent bioimaging, with higher tumor-to-background ratios, allows for the accurate delineation of tumor boundaries from healthy tissue. Guided by second-near-infrared region (NIR II, 1000-1700 nm) luminescence imaging, tumors are entirely removed, resulting in minimal in situ tumor recurrence or multiorgan metastasis within 30 days postsurgery. Furthermore, with 808 nm laser illumination, the nanoplatform demonstrates a satisfactory photothermal conversion ability, which induces localized tumor thermal and further enhances ROS generation through the synergistic action of bimetallic ions, facilitating CRC cell destruction. These findings highlight the promising potential of Ce-Se oxide nanocomposites with tumor-microenvironment stimuli as a fluorescence bioimaging contrast agent and oxidative therapy nanoagent for cancer eradication, particularly under laser activation.
- Open Access
- 11 July 2025
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 21 (10) , 4604-4628
Harnessing Natural Products to Surmount Drug Resistance in Gastric Cancer: Mechanisms and Therapeutic Perspectives
Gastric cancer remains a major cause of mortality. The current standard of care of gastric cancer is based upon combination chemotherapy comprising platinum, fluoropyrimidines drugs and docetaxel. However, the efficacy of chemotherapy is hindered by intrinsic and acquired drug resistance, resulting in poor patient prognosis. Studies are currently exploring the potential of immunotherapy and other biologically targeted agents in the perioperative setting. To select the most efficacious therapy for advanced gastric cancer, including adenocarcinoma of the esophago-gastric junction, it is essential to determine key biomarkers including for example human epidermal growth factor receptor 2 (HER2) expression, programmed death-ligand 1 (PD-L1) combined positive score (CPS), Claudin 18.2, and microsatellite instability (MSI). Moreover, recent studies have highlighted the potential of natural products as effective agents in surmounting anticancer drug resistance in gastric cancer. These bioactive compounds exhibit various antitumor activities, including induction of apoptosis, inhibition of cell proliferation, modulation of autophagy, and most importantly reversal of distinct multidrug resistance (MDR) modalities. The present review provides a comprehensive analysis of the mechanisms underlying chemoresistance in gastric cancer and explores how natural products can overcome distinct MDR mechanisms. We further discuss the therapeutic potential of combining natural products with established chemotherapeutics and immunotherapy agents to enhance treatment efficacy and reduce adverse effects.
- 11 July 2025
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 21 (10) , 4604-4628
Open AccessHarnessing Natural Products to Surmount Drug Resistance in Gastric Cancer: Mechanisms and Therapeutic Perspectives
Gastric cancer remains a major cause of mortality. The current standard of care of gastric cancer is based upon combination chemotherapy comprising platinum, fluoropyrimidines drugs and docetaxel. However, the efficacy of chemotherapy is hindered by intrinsic and acquired drug resistance, resulting in poor patient prognosis. Studies are currently exploring the potential of immunotherapy and other biologically targeted agents in the perioperative setting. To select the most efficacious therapy for advanced gastric cancer, including adenocarcinoma of the esophago-gastric junction, it is essential to determine key biomarkers including for example human epidermal growth factor receptor 2 (HER2) expression, programmed death-ligand 1 (PD-L1) combined positive score (CPS), Claudin 18.2, and microsatellite instability (MSI). Moreover, recent studies have highlighted the potential of natural products as effective agents in surmounting anticancer drug resistance in gastric cancer. These bioactive compounds exhibit various antitumor activities, including induction of apoptosis, inhibition of cell proliferation, modulation of autophagy, and most importantly reversal of distinct multidrug resistance (MDR) modalities. The present review provides a comprehensive analysis of the mechanisms underlying chemoresistance in gastric cancer and explores how natural products can overcome distinct MDR mechanisms. We further discuss the therapeutic potential of combining natural products with established chemotherapeutics and immunotherapy agents to enhance treatment efficacy and reduce adverse effects.
- Open Access
- 11 July 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1551224
Baseline MRI habitat imaging for predicting treatment response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
Purpose: This study was to assess whether baseline magnetic resonance habitat imaging can predict the efficacy of neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC).Methods: This retrospective study analyzed data from 181 patients with locally advanced rectal cancer, including 60 who exhibited a good treatment response. The cohort was randomly divided into a training set (127 patients, 42 with good response) and a validation set (54 patients, 18 with good response). Five models were developed: ModelClinic, ModelRadiomics, ModelHabitat, ModelClinic+Radiomics, and ModelClinic+Habitat. Model performance was assessed using the area under the receiver operating characteristic (ROC) curve (AUC) for both training and validation sets.Results: The AUC values for predicting the efficacy of LARC neoadjuvant therapy were as follows: in the training set, ModelClinic achieved 0.788, ModelRadiomics 0.827, ModelHabitat 0.815, ModelClinic+Radiomics 0.938, and ModelClinic+Habitat 0.896; in the test set, the corresponding AUCs were 0.656, 0.619, 0.636, 0.532, and 0.710, respectively. Decision curve analysis demonstrated that the clinical combined habitat model (ModelClinic+Habitat) provided higher net benefits than other models within a threshold probability range of 20% to 80%.Conclusion: The habitat model we developed, which integrates first-order and clinical features, demonstrates potential for predicting the efficacy of nCRT clinically interpretable spatial heterogeneity information. This model may aid in personalized treatment decision-making for LARC.
- 11 July 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1551224
Open AccessBaseline MRI habitat imaging for predicting treatment response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
Purpose: This study was to assess whether baseline magnetic resonance habitat imaging can predict the efficacy of neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC).Methods: This retrospective study analyzed data from 181 patients with locally advanced rectal cancer, including 60 who exhibited a good treatment response. The cohort was randomly divided into a training set (127 patients, 42 with good response) and a validation set (54 patients, 18 with good response). Five models were developed: ModelClinic, ModelRadiomics, ModelHabitat, ModelClinic+Radiomics, and ModelClinic+Habitat. Model performance was assessed using the area under the receiver operating characteristic (ROC) curve (AUC) for both training and validation sets.Results: The AUC values for predicting the efficacy of LARC neoadjuvant therapy were as follows: in the training set, ModelClinic achieved 0.788, ModelRadiomics 0.827, ModelHabitat 0.815, ModelClinic+Radiomics 0.938, and ModelClinic+Habitat 0.896; in the test set, the corresponding AUCs were 0.656, 0.619, 0.636, 0.532, and 0.710, respectively. Decision curve analysis demonstrated that the clinical combined habitat model (ModelClinic+Habitat) provided higher net benefits than other models within a threshold probability range of 20% to 80%.Conclusion: The habitat model we developed, which integrates first-order and clinical features, demonstrates potential for predicting the efficacy of nCRT clinically interpretable spatial heterogeneity information. This model may aid in personalized treatment decision-making for LARC.
- Open Access
- 9 July 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-14
UBC9 overexpression promotes proliferation and metastasis in gastric cancer via ATF2
Gastric cancer remains a leading cause of cancer-related mortality worldwide, characterized by poor prognosis due to its aggressive nature and high metastatic potential. While the E2-conjugating enzyme UBE2I (UBC9), essential for SUMOylation, has been implicated in various cancers, its precise role in gastric cancer remains poorly understood. In the study, we demonstrate significant UBC9 overexpression in gastric cancer tissues, which correlates with poor clinical outcomes. Functional analyses revealed that UBC9 knockdown significantly suppressed gastric cancer cell proliferation, migration, and invasion in vitro and in vivo, whereas UBC9 overexpression enhanced these malignant phenotypes. Through integrated transcriptomic and proteomic analyses, we identified ATF2 (Activating Transcription Factor 2) as a crucial downstream effector of UBC9-mediated oncogenic signaling. The mechanistic relationship between these factors was confirmed as ATF2 knockdown substantially attenuated the oncogenic effects of UBC9 overexpression. This newly identified UBC9-ATF2 regulatory axis promotes gastric cancer progression by enhancing cellular proliferation and metastatic potential. Our findings establish UBC9 and ATF2 as promising prognostic biomarkers and potential therapeutic targets, suggesting that intervention in the UBC9-ATF2 axis may provide novel therapeutic strategies for inhibiting gastric cancer progression and improving patient outcomes.
- 9 July 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-14
Open AccessUBC9 overexpression promotes proliferation and metastasis in gastric cancer via ATF2
Gastric cancer remains a leading cause of cancer-related mortality worldwide, characterized by poor prognosis due to its aggressive nature and high metastatic potential. While the E2-conjugating enzyme UBE2I (UBC9), essential for SUMOylation, has been implicated in various cancers, its precise role in gastric cancer remains poorly understood. In the study, we demonstrate significant UBC9 overexpression in gastric cancer tissues, which correlates with poor clinical outcomes. Functional analyses revealed that UBC9 knockdown significantly suppressed gastric cancer cell proliferation, migration, and invasion in vitro and in vivo, whereas UBC9 overexpression enhanced these malignant phenotypes. Through integrated transcriptomic and proteomic analyses, we identified ATF2 (Activating Transcription Factor 2) as a crucial downstream effector of UBC9-mediated oncogenic signaling. The mechanistic relationship between these factors was confirmed as ATF2 knockdown substantially attenuated the oncogenic effects of UBC9 overexpression. This newly identified UBC9-ATF2 regulatory axis promotes gastric cancer progression by enhancing cellular proliferation and metastatic potential. Our findings establish UBC9 and ATF2 as promising prognostic biomarkers and potential therapeutic targets, suggesting that intervention in the UBC9-ATF2 axis may provide novel therapeutic strategies for inhibiting gastric cancer progression and improving patient outcomes.
- Open Access
- 1 July 2025
- Published by Tsinghua University Press in Nano Research
- Vol. 18 (7)
Uniformed mesoporous silica with unique chiral architecture for enhanced endocytosis and fluorescence imaging
Chiral nanomaterials hold significant promise for enhancing clinical therapeutic outcomes, thanks to their unique chiral selectivity in biological systems. Despite this potential, the innovative approach has garnered limited focus in the realm of cancer therapy. In this work, we synthesize multi-shelled mesoporous silica nanocarriers by a biphasic stratification reaction system. Owing to a lamellar micelle spiral self-assembly happens at the water/oil bio-interface, the fabricated silica nanosphere has a unique chirality which is different from conventional dendritic mesoporous silica nanoparticles. On one hand, after loading with the clinically approved dye molecule ICG, the long-off peak fluorescence at second Near-infrared window (NIR II, 1000-1700 nm) exhibits excellent photostability, with a significant enhancement in under continuous exposure to daylight or an 808 nm laser, which is highly beneficial for long-duration surgical navigation in clinical settings. On the other hand, due to its unique chiral architecture, chiral Si nanocarriers demonstrate unparalleled cellular uptake capability compared to traditional mesoporous silica. Furthermore, thanks to cSi's targeted accumulation in tumor tissues and its ability to synergistically promote photothermal augmented chiral-specific tumor cell killing, the malignant tissue is effectively suppressed, heralding a new way in cancer-fighting.
- 1 July 2025
- Published by Tsinghua University Press in Nano Research
- Vol. 18 (7)
Open AccessUniformed mesoporous silica with unique chiral architecture for enhanced endocytosis and fluorescence imaging
Chiral nanomaterials hold significant promise for enhancing clinical therapeutic outcomes, thanks to their unique chiral selectivity in biological systems. Despite this potential, the innovative approach has garnered limited focus in the realm of cancer therapy. In this work, we synthesize multi-shelled mesoporous silica nanocarriers by a biphasic stratification reaction system. Owing to a lamellar micelle spiral self-assembly happens at the water/oil bio-interface, the fabricated silica nanosphere has a unique chirality which is different from conventional dendritic mesoporous silica nanoparticles. On one hand, after loading with the clinically approved dye molecule ICG, the long-off peak fluorescence at second Near-infrared window (NIR II, 1000-1700 nm) exhibits excellent photostability, with a significant enhancement in under continuous exposure to daylight or an 808 nm laser, which is highly beneficial for long-duration surgical navigation in clinical settings. On the other hand, due to its unique chiral architecture, chiral Si nanocarriers demonstrate unparalleled cellular uptake capability compared to traditional mesoporous silica. Furthermore, thanks to cSi's targeted accumulation in tumor tissues and its ability to synergistically promote photothermal augmented chiral-specific tumor cell killing, the malignant tissue is effectively suppressed, heralding a new way in cancer-fighting.
- Open Access
- 3 June 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (11) , e70621
Evaluating the Potential of COL8A1 as a Therapeutic Target for Chemoresistance, Disease Progression, and a Prognostic Marker in Gastric Cancer
This study aimed to identify key genes associated with post‐chemotherapy recurrence in gastric cancer patients. Gene expression data from multiple cohorts were analysed to determine differentially expressed genes between recurrent and non‐recurrent cases. A prognostic risk model incorporating COL8A1, HSPB7 and SLIT2 was developed and validated across six independent cohorts. The risk score demonstrated significant associations with disease‐free and overall survival, tumour grade and molecular subtypes. Notably, the risk score showed potential as a predictor of immunotherapy response, outperforming established markers such as microsatellite instability score and Epstein–Barr virus status. Analysis of the tumour immune microenvironment revealed a correlation between risk score and M2 macrophage infiltration. A nomogram integrating the risk score with clinical factors demonstrated high accuracy in predicting patient survival. Further investigation of COL8A1 revealed its significant role in gastric cancer cell proliferation, metastasis, and chemoresistance. In vitro and in vivo experiments showed that COL8A1 knockdown inhibited cancer cell growth, invasion, and metastasis while enhancing chemosensitivity. These findings provide valuable insights into the molecular mechanisms of gastric cancer recurrence and offer potential biomarkers for prognosis and treatment response prediction. The study highlights the importance of integrating genomic data with clinical information to improve patient stratification and personalised treatment strategies in gastric cancer management.
- 3 June 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (11) , e70621
Open AccessEvaluating the Potential of COL8A1 as a Therapeutic Target for Chemoresistance, Disease Progression, and a Prognostic Marker in Gastric Cancer
This study aimed to identify key genes associated with post‐chemotherapy recurrence in gastric cancer patients. Gene expression data from multiple cohorts were analysed to determine differentially expressed genes between recurrent and non‐recurrent cases. A prognostic risk model incorporating COL8A1, HSPB7 and SLIT2 was developed and validated across six independent cohorts. The risk score demonstrated significant associations with disease‐free and overall survival, tumour grade and molecular subtypes. Notably, the risk score showed potential as a predictor of immunotherapy response, outperforming established markers such as microsatellite instability score and Epstein–Barr virus status. Analysis of the tumour immune microenvironment revealed a correlation between risk score and M2 macrophage infiltration. A nomogram integrating the risk score with clinical factors demonstrated high accuracy in predicting patient survival. Further investigation of COL8A1 revealed its significant role in gastric cancer cell proliferation, metastasis, and chemoresistance. In vitro and in vivo experiments showed that COL8A1 knockdown inhibited cancer cell growth, invasion, and metastasis while enhancing chemosensitivity. These findings provide valuable insights into the molecular mechanisms of gastric cancer recurrence and offer potential biomarkers for prognosis and treatment response prediction. The study highlights the importance of integrating genomic data with clinical information to improve patient stratification and personalised treatment strategies in gastric cancer management.
- Open Access
- 14 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Comparison of [99mTc]Tc-FAPI SPECT/CT and [18F]FDG PET/CT as predictive biomarkers for immunotherapy response in gastrointestinal cancer
To explore the diagnostic performance of [99mTc]Tc-FAPI SPECT/CT for gastrointestinal cancer, compared to [18F]FDG PET/CT. In this analysis of a prospective trial, consecutively recruited patients from a single center with pathologically confirmed gastrointestinal cancer were prospectively enrolled from September 2022 to June 2024 and underwent paired v and [18F]FDG PET/CT examinations at intervals of more than 1 day and within 7 days of each other.The activity of tracer accumulation in lesions was assessed by maximum standardized uptake value(SUVmax) and TBR (lesions SUVmax/ascending aorta SUVmean). Histopathologic and clinical follow-up results were used as reference standards for final diagnoses. Seventy-eight patients (46 men; median age, 58.8 ± 14.5 years) were evaluated. Compared with the TBR for [18F]FDG uptake, TBR for [99mTc]Tc-FAPI uptake was higher in primary tumor(4.6 ± 2.0 vs. 3.4 ± 1.7; P = 0.001) ,peritoneal spread (1.3 [1.1,7.3] vs. 1.1[1.1,1.1]; P = 0.001 ) and liver metastases( 2.5[1.1,8.5] vs. 1.1[1.1,3.4]; P = 0.031). For diagnostic accuracy in a total of 253 lesions in 78 patients, compared with [18F]FDG PET/CT, [99mTc]Tc-FAPI SPECT/CT demonstrated a higher sensitivity (100% [15 of 15 lesions] vs. 20% [3 of 15]; P < 0.001), accuracy (100% [48 of 48 lesions] vs. 75% [36 of 48];P < 0.001), and negative predictive value (100% [33 of 33 lesions] vs. 69% [36 of 48 lesions]; P = 0 0.001) in detecting peritoneal spread, and a higher sensitivity (85% [17 of 20 lesions] vs. 50% [10 of 20]; P = 0.041) in detecting liver metastases. Patients with metastatic gastrointestinal carcinomas negative on the [99mTc]Tc-FAPI scan showed improved clinical prognosis after immunotherapy (P<0.006). TBR-FDG/TBR-FAPI was the main predictor of better prognosis post-immunotherapy ([stable disease, SD]+[partial response, PR]), with an optimal cut-off of 3.82. [99mTc]Tc-FAPI SPECT/CT can better evaluate peritoneal spread and liver metastases in gastrointestinal cancer. Furthermore, TBR-FDG/TBR-FAPI is a valuable imaging parameter for monitoring immunotherapy responses.
- 14 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Open AccessComparison of [99mTc]Tc-FAPI SPECT/CT and [18F]FDG PET/CT as predictive biomarkers for immunotherapy response in gastrointestinal cancer
To explore the diagnostic performance of [99mTc]Tc-FAPI SPECT/CT for gastrointestinal cancer, compared to [18F]FDG PET/CT. In this analysis of a prospective trial, consecutively recruited patients from a single center with pathologically confirmed gastrointestinal cancer were prospectively enrolled from September 2022 to June 2024 and underwent paired v and [18F]FDG PET/CT examinations at intervals of more than 1 day and within 7 days of each other.The activity of tracer accumulation in lesions was assessed by maximum standardized uptake value(SUVmax) and TBR (lesions SUVmax/ascending aorta SUVmean). Histopathologic and clinical follow-up results were used as reference standards for final diagnoses. Seventy-eight patients (46 men; median age, 58.8 ± 14.5 years) were evaluated. Compared with the TBR for [18F]FDG uptake, TBR for [99mTc]Tc-FAPI uptake was higher in primary tumor(4.6 ± 2.0 vs. 3.4 ± 1.7; P = 0.001) ,peritoneal spread (1.3 [1.1,7.3] vs. 1.1[1.1,1.1]; P = 0.001 ) and liver metastases( 2.5[1.1,8.5] vs. 1.1[1.1,3.4]; P = 0.031). For diagnostic accuracy in a total of 253 lesions in 78 patients, compared with [18F]FDG PET/CT, [99mTc]Tc-FAPI SPECT/CT demonstrated a higher sensitivity (100% [15 of 15 lesions] vs. 20% [3 of 15]; P < 0.001), accuracy (100% [48 of 48 lesions] vs. 75% [36 of 48];P < 0.001), and negative predictive value (100% [33 of 33 lesions] vs. 69% [36 of 48 lesions]; P = 0 0.001) in detecting peritoneal spread, and a higher sensitivity (85% [17 of 20 lesions] vs. 50% [10 of 20]; P = 0.041) in detecting liver metastases. Patients with metastatic gastrointestinal carcinomas negative on the [99mTc]Tc-FAPI scan showed improved clinical prognosis after immunotherapy (P<0.006). TBR-FDG/TBR-FAPI was the main predictor of better prognosis post-immunotherapy ([stable disease, SD]+[partial response, PR]), with an optimal cut-off of 3.82. [99mTc]Tc-FAPI SPECT/CT can better evaluate peritoneal spread and liver metastases in gastrointestinal cancer. Furthermore, TBR-FDG/TBR-FAPI is a valuable imaging parameter for monitoring immunotherapy responses.